241 related articles for article (PubMed ID: 9367793)
1. Therapeutic potential and mechanism of action of oligonucleotides and ribozymes.
Lavrovsky Y; Chen S; Roy AK
Biochem Mol Med; 1997 Oct; 62(1):11-22. PubMed ID: 9367793
[TBL] [Abstract][Full Text] [Related]
2. Oligonucleotide-based antiviral strategies.
Schubert S; Kurreck J
Handb Exp Pharmacol; 2006; 173(173):261-87. PubMed ID: 16594620
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic oligonucleotides.
Goodchild J
Methods Mol Biol; 2011; 764():1-15. PubMed ID: 21748630
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic antisense and ribozymes.
Rossi JJ
Br Med Bull; 1995 Jan; 51(1):217-25. PubMed ID: 7767645
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of oligonucleotide-based therapy in cardiovascular disease.
Morishita R; Kaneda Y; Ogihara T
BioDrugs; 2003; 17(6):383-9. PubMed ID: 14614761
[TBL] [Abstract][Full Text] [Related]
6. Nucleic acid modulation of gene expression: approaches for nucleic acid therapeutics against cancer.
Nakata Y; Kim TK; Shetzline S; Gewirtz AM
Crit Rev Eukaryot Gene Expr; 2005; 15(2):163-82. PubMed ID: 16022634
[TBL] [Abstract][Full Text] [Related]
7. [Oligonucleotide therapeutics - an emerging novel class of compounds].
Wacheck V
Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
[TBL] [Abstract][Full Text] [Related]
8. Oligonucleotide-mediated modulation of mammalian gene expression.
Scanlon KJ; Ohta Y; Ishida H; Kijima H; Ohkawa T; Kaminski A; Tsai J; Horng G; Kashani-Sabet M
FASEB J; 1995 Oct; 9(13):1288-96. PubMed ID: 7557018
[TBL] [Abstract][Full Text] [Related]
9. To cleave or not to cleave: ribozymes and antisense.
Woolf TM
Antisense Res Dev; 1995; 5(3):227-32. PubMed ID: 8785479
[No Abstract] [Full Text] [Related]
10. [Specific control of gene expression by oligonucleotides: from chemistry to clinical aspects].
Hélène C
Ann Pharm Fr; 1997; 55(3):95-103. PubMed ID: 9239858
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotides: the state of the art.
Aboul-Fadl T
Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
[TBL] [Abstract][Full Text] [Related]
12. Design and applications of modified oligonucleotides.
Gallo M; Montserrat JM; Iribarren AM
Braz J Med Biol Res; 2003 Feb; 36(2):143-51. PubMed ID: 12563516
[TBL] [Abstract][Full Text] [Related]
13. Hammerhead ribozymes for target validation.
Goodchild J
Expert Opin Ther Targets; 2002 Apr; 6(2):235-47. PubMed ID: 12223083
[TBL] [Abstract][Full Text] [Related]
14. Targeting human telomerase by antisense oligonucleotides and ribozymes.
Folini M; Pennati M; Zaffaroni N
Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):605-12. PubMed ID: 12678727
[TBL] [Abstract][Full Text] [Related]
15. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
16. Strategies to identify potential therapeutic target sites in RNA.
Lützelberger M; Kjems J
Handb Exp Pharmacol; 2006; (173):243-59. PubMed ID: 16594619
[TBL] [Abstract][Full Text] [Related]
17. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
Kronenwett R; Haas R; Sczakiel G
J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
[TBL] [Abstract][Full Text] [Related]
18. The potential application of ribozymes for the treatment of hematological disorders.
James HA
J Leukoc Biol; 1999 Sep; 66(3):361-8. PubMed ID: 10496304
[TBL] [Abstract][Full Text] [Related]
19. Antisense applications for biological control.
Pan WH; Clawson GA
J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
[TBL] [Abstract][Full Text] [Related]
20. Antisense technologies have a future fighting neurodegenerative diseases.
Seidman S; Eckstein F; Grifman M; Soreq H
Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):333-40. PubMed ID: 10463077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
